Update On Aastrom's Cardiovascular Programs to be Presented At Transcatheter Cardiovascular Therapeutics Annual Meeting by Amit N. Patel, M.D. Sep 23, 2009
Source: Aastrom Biosciences, Inc. ... Sept. 22, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq: - ), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced today that Dr. Amit N. Patel, Associate Professor of Surgery at the University of Utah School of Medicine and National Principal Investigator of the Company's U.S. Phase II IMPACT-DCM clinical trial, will provide an overview of Aastrom's cardiovascular programs at the... (Primezone Releases)
Stem-cell drug fails crucial trials Sep 10, 2009
Shares in a variety of other stem-cell companies, including Australia s Mesoblast, and California s Geron and StemCells, and Michigan s Aastrom Biosciences, were unaffected. Unusual approach. (Scientific American)
Aastrom Announces Transitions in Senior Management Sep 4, 2009
Source: Aastrom Biosciences, Inc. ... Sept. 3, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq: - ), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced an executive management transition process that will strengthen and expand the senior leadership team over the next several months ... About Aastrom Biosciences, Inc.. (Primezone Releases)
Aastrom Biosciences Receives Notification That NASDAQ Further Extends Suspension of Certain Continued Listing Requirements Mar 24, 2009
Press Release Source: Aastrom Biosciences, Inc. ... March 23, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM: - ), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced that the Company received Issuer Alert #2009-002 from The Nasdaq Stock Market LLC (``NASDAQ'') ... About Aastrom Biosciences, Inc.. (Primezone Releases)
FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial Mar 4, 2009
Source: Aastrom Biosciences, Inc. ... March 3, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM: - ), a leading regenerative medicine company, today reported that the U.S. Food and Drug Administration (FDA) has removed the clinical hold from the Company's U.S. Phase II IMPACT-DCM clinical trial and that patient enrollment would resume at the four initiated clinical sites ... About Aastrom Biosciences, Inc.. (Primezone Releases)
